|
More sensitive test norms better predict
who might develop Alzheimer's disease
By
Pam Willenz, the American Psychological Association Early diagnosis of Alzheimer's has taken on
growing importance, given new medical and psychological interventions that
can slow (but not stop) the course of the disease. In addition, highly
intelligent people have been found, on average, to show clinical signs of
Alzheimer's later than the general population. Once they do, they decline
much faster. Thought to reflect their greater mental reserves, this
different pattern may call for a different approach to diagnosis. Says lead author Dorene Rentz, PsyD,
"Highly intelligent elders are often told their memory changes are
typical of normal aging when they are not. As a result, they would miss
the advantages of disease-modifying medications when they become
available." Rentz, of Brigham and Women's Hospital's
Department of Neurology and Harvard Medical School, led her co-authors in
a study of 42 older people with IQ's of 120 or more, drawn from a
longitudinal study of aging and Alzheimer's Disease. Rentz and her
colleagues analyzed participant performance on measures of cognitive
ability, such as word generation, memory and visuospatial processing, with
scores gathered at the start of the study and three-and-a-half years
later. Then, they asked which of two different test norms forecast
problems: The standard norm, derived from a large cross-section of the
population, or an adjusted high-IQ norm that measured changes against the
individual's higher ability level? The raised cutoffs worked better. For memory
scores obtained at baseline, raised cutoffs predicted that 11 of the 42
individuals were at risk for future decline – compared with standard
cutoffs, which indicated they were normal. But, what's normal for people
of average IQ isn't normal for people of higher IQ: True to the former
prediction, three and a half years later, nine of those 11 people had
declined. Six of those went on to develop mild cognitive impairment (MCI),
a transitional illness from normal aging to a dementia (of which one type
is Alzheimer's). Five of these individuals have since received a diagnosis
of Alzheimer's disease, two years after this study was submitted. "With standard norms, people with
higher levels of ability would be classified as normal for up to three
years before they began demonstrating a decline on standardized
tests," says Rentz. "In this case, they could be at risk for not
receiving early treatment intervention." The statistical approach was simple. High-IQ
people were scored against an average that was "normal" for
them, proportionately higher than the cross-sectional average of 100.
Scores were considered abnormal if, according to standard practice, they
were 1.5 standard deviations or more below the (adjusted) norm. Rentz and her co-authors believe that by the
same reasoning, adjusted norms could help people at the other end of the
scale. "People with below-average intelligence have the potential for
being misdiagnosed as 'demented' when they are not, because they score
below the normative cutoffs," explains Rentz. Adjusting norms to
match the ability level of the person being evaluated, she believes, could
have the greatest predictive power in detecting the early signs of an
incipient Alzheimer's-type dementia. Rentz points out that for women, adjusting
for IQ may be particularly useful compared with traditional adjustments
for education. "Education-based methods often underestimate ability
in women who did not have the same educational advantages as men,
particularly in this aged cohort," she says. The authors also report that IQ-adjusted
norms might help to control for some inaccuracies that have filtered into
normative data, as these norms were derived from cross-sectional
populations who might not have been adequately screened for preclinical
Alzheimer's disease. Because it could take a long time to develop new
databases from longitudinal studies, the authors say that the "use of
an IQ-adjusted method may provide a temporary solution for clinicians and
research investigators evaluating older highly intelligent individuals at
risk for Alzheimer's disease."
*** (Full text of the article is available from
the APA Public Affairs Office) Dorene Rentz can be reached by email at drentz@partners.org
or by phone at 617-732-8235. She can also be reached through a publicist,
Melanie Franco, 617-534-1605 or mfranco1@partners.org.
The American Psychological Association (APA), in Copyright © 2002
Global Action on Aging |